ANDA 215466, held by Regcon Holdings. Minocycline Hydrochloride.
As of Nov 22, 2026, ANDA 215466 (Minocycline Hydrochloride), held by Regcon Holdings, was first approved by FDA on May 27, 2022, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 27, 2022 | Original application | Approved | None posted |
| Minocycline HydrochlorideEQ 50MG BASE · tablet;oral | Minocycline Hydrochloride | Rx |
| Minocycline HydrochlorideEQ 75MG BASE · tablet;oral | Minocycline Hydrochloride | Rx |
| Minocycline HydrochlorideEQ 100MG BASE · tablet;oral | Minocycline Hydrochloride | Rx |
| Mar 31, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 27, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters